My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
AG 2018 01 16
CabarrusCountyDocuments
>
Public Meetings
>
Agendas
>
BOC
>
2018
>
AG 2018 01 16
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
5/8/2019 12:39:30 PM
Creation date
5/1/2019 12:22:35 PM
Metadata
Fields
Template:
Meeting Minutes
Doc Type
Agenda
Meeting Minutes - Date
1/16/2018
Board
Board of Commissioners
Meeting Type
Regular
Jump to thumbnail
< previous set
next set >
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
260
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
DRUG AND ALCOHOL POLICY ADDENDUM <br />EFFECTIVE: JANUARY 1, 2018 <br />The United States Department of Transportation (USDOT) - Office of Drug and Alcohol Policy and <br />Compliance (ODAPC) has issued an update to USDOT's drug and alcohol testing regulation (49 CFR Part <br />40). The new regulation has been revised and the changes (summarized below) will become effective on <br />January 1, 2018. Therefore, the Cabarrus County drug and alcohol testing policy is amended as follows: <br />1. CHANGES TO THE DRUG TESTING PANEL <br />a. Four new opioids added to the drug testing panel - <br />i. The USDOT drug test remains a "5 -panel" drug test; however, the list of opioids for <br />which are tested will expand from three to seven opioids. <br />ii. The "opioid" category will continue to test for codeine, morphine, and heroin; <br />however, the "opioid" testing panel will now be expanded to include four (4) new <br />semi -synthetic opioids: <br />1. (1) Hydrocodone, (2) Hydromorphone, (3) Oxycodone, and (4) <br />Oxymorphone. <br />2. Common brand names for these semi -synthetic opioids include, but may not <br />be limited to: OxyContin®, Percodan®, Percocet®, Vicodin ®, Lortab®, <br />Norco®, Dilaudid®, Exalgo®. <br />b. 'MDA' will be tested as an initial test analyte <br />c. 'MDEA' will no longer be tested for under the "amphetamines" category. <br />2. BLIND SPECIMEN TESTING <br />a. The USDOT no longer requires blind specimens to be submitted to laboratories. <br />3. ADDITIONS TO THE LIST OF "FATAL FLAWS" <br />a. The following three circumstances have been added to the list of "fatal Flaws": <br />4. <br />i. No CCF received by the laboratory with the urine specimen. <br />ii. In cases where a specimen has been collected, there was no specimen submitted <br />with the CCF to the laboratory. <br />iii. Two separate collections are performed using one CCF. <br />a. When a tested employee is taking a prescribed medication, after verifying the prescription <br />and immediately notifying the employer of a verified negative result, the MRO must then <br />(after notifying the employee) wait five (5) business days to be contacted by the <br />21 <br />AWachmenl number 1 \n <br />F-5 Page 76 <br />
The URL can be used to link to this page
Your browser does not support the video tag.